Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yammy YungEmily LeeHiu-Tung ChuPui-Kwan YipHarinder GillPublished in: International journal of molecular sciences (2021)
Myeloproliferative neoplasms (MPNs) are unique hematopoietic stem cell disorders sharing mutations that constitutively activate the signal-transduction pathways involved in haematopoiesis. They are characterized by stem cell-derived clonal myeloproliferation. The key MPNs comprise chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). CML is defined by the presence of the Philadelphia (Ph) chromosome and BCR-ABL1 fusion gene. Despite effective cytoreductive agents and targeted therapy, complete CML/MPN stem cell eradication is rarely achieved. In this review article, we discuss the novel agents and combination therapy that can potentially abnormal hematopoietic stem cells in CML and MPNs and the CML/MPN stem cell-sustaining bone marrow microenvironment.
Keyphrases
- chronic myeloid leukemia
- stem cells
- bone marrow
- combination therapy
- hematopoietic stem cell
- copy number
- induced apoptosis
- mesenchymal stem cells
- social media
- healthcare
- genome wide
- cell cycle arrest
- health information
- acute lymphoblastic leukemia
- signaling pathway
- oxidative stress
- tyrosine kinase
- genome wide analysis